ProfileGDS5678 / 1450682_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 59% 59% 59% 57% 66% 61% 59% 58% 57% 61% 57% 57% 60% 59% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.6000159
GSM967853U87-EV human glioblastoma xenograft - Control 23.5239459
GSM967854U87-EV human glioblastoma xenograft - Control 33.5186159
GSM967855U87-EV human glioblastoma xenograft - Control 43.4068857
GSM967856U87-EV human glioblastoma xenograft - Control 53.9735466
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.7120461
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.6097559
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.4886758
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.4461557
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.615161
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.451957
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.4125857
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.6100360
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.5150859